COMPANY:

SeekIn

"SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, today announced three additional validation studies that evaluate OncoSeek's ability to detect more than nine cancer types and predict the tissue of origin with a tube of blood. The data further validate the performance of OncoSeek with consistent results between the three new cohorts and the three previous cohorts of ~12,000 participants from China, the United States and Brazil. The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms."

"SeekIn Inc...announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE."

"SeekIn Inc...announced the validation studies consisting of one retrospective cohort and one prospective cohort that evaluate SeekInCare's ability to detect cancer patients and predict the tissue of origin with one tube of blood. The results demonstrate the performance of SeekInCare with the consistent results among the two cohorts in ~2,400 cancer patients and non-cancer individuals. SeekInCare achieved overall 65.5% sensitivity at 97.9% specificity in the retrospective studies and 60.0% sensitivity at 96.1% specificity in the prospective cohort study, respectively, which is best-in-class in blood-based multi-cancer early detection (MCED). The findings were presented at the 20th ICGC Workshop and 7th ARGO Meeting in New York."

"SeekIn Inc...announced two additional validation studies that evaluate OncoSeek's ability to detect more than nine cancer types and predict the tissue of origin with a tube of blood. The data further validate the performance of OncoSeek with the consistent results between the two new cohorts and the three previous cohorts of ~10,000 participants from China and the United States."

"Monoceros Biosystems...is thrilled to announce a strategic partnership with SeekIn...The partnership represents a significant milestone in the quest to advance cancer early detection and disease monitoring through state-of-the-art genomics and bioinformatics expertise...The collaboration between Monoceros Biosystems and SeekIn is poised to reshape the landscape of cancer diagnostics, offering new hope for early detection and more effective monitoring. This partnership brings together the best innovation to benefit patients globally."

"SeekIn Inc...announces the participation of Dr. Mao, CEO and Co-founder, in the highly anticipated BIOHK2023 conference. The CEO took the stage to deliver an engaging presentation, shedding light on the technological roadmap, exceptional performance, and extensive applications of their groundbreaking multi-cancer early detection product, called OncoSeek."

"SeekIn Inc...announces its participation in the prestigious ASCO Breakthrough Conference. The event takes place in Yokohama Japan on August 3-5, 2023...The second abstract presents a prospective study that utilizes SeekInClarity®, a pan-cancer, non-invasive efficacy detection technology, to evaluate treatment response and prognosis prediction in lymphoma patients."

"SeekIn Inc...announced that a research article titled 'A panel of seven protein tumor markers for effective and affordable multicancer early detection by artificial intelligence' has been published in eClinicalMedicine, a clinical journal published by The Lancet. This is a major breakthrough for SeekIn's multi-cancer early detection (MCED) tests in the oncology field, and a high recognition of SeekIn's technical strength and research & development capabilities."

"SeekIn Inc...announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark...PanCanSeek® is developed as the world's first integrated solution for leukemia cytogenetics and molecular diagnostics. It uses high-depth WGS, which can cover four different detection techniques – karyotyping for CNV, FISH for gene fusion, qPCR for single mutation and targeted NGS panel for multiple mutations."

"SeekIn Inc...today announced CE (Conformité Européenne) Mark approval for SeekInCure Cancer Recurrence Monitoring Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark."

"SeekIn Inc...announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity®, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States...study presents a strong demonstration that SeekInClarity can be considered an in vivo drug sensitivity test."

"SeekIn Inc...announced the results of pan-cancer early detection test SeekInCare® were presented at The 2022 Early Detection of Cancer Conference in Portland, Oregon."

"SeekIn Inc...announced CE (Conformité Européenne) Mark approval for OncoSeek® Multi-Cancer Detection Test and is now ready to launch this test in European Union and other countries that recognize CE mark...OncoSeek®, a customized panel of seven selected protein tumor markers (PTMs) including AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1, quantified them on Roche cobas e411 instrument performing for 12 common cancers early detection."

"SeekIn said...that it has received CE marking for its SeekInClarity Cancer Treatment Response Monitoring Kit...The Shenzhen, China-based biotech said that it is now ready to launch the kit in Europe and other countries that recognize the CE mark...The liquid biopsy assesses cancer treatment response through changes in circulating tumor DNA."

"SeekIn said on Thursday that it has received CE marking for its LeukoPrint Molecular Karyotyping Kit for the diagnosis and stratification of leukemia patients...LeukoPrint uses shallow whole-genome sequencing to identify copy number aberrations (CNA) in blood samples from leukemia patients to assist in diagnostic classification and risk stratification."

"SeekIn Inc...announced the CE (Conformité Européenne) Mark for SeekInCare® Cancer Detection Kit and is now ready to launch this test in European markets."